C0008838||cisplatin
C0011777||dexamethasone
C0045093||gemcitabine
C0071568||pegaspargase
C1254351||dexamethasone, gemcitabine and pegaspargase
C0040808||regimen
C1955906||extranodal natural killer/T-cell lymphoma
C0936012||analysis
C2603343||study
C0392788||extranodal natural killer/T-cell lymphoma, nasal type
C0392788||extranodal natural killer/T-cell lymphoma, nasal type
C2603343||study
C0008838||cisplatin
C0011777||dexamethasone
C0045093||gemcitabine
C0071568||pegaspargase
C1254351||dexamethasone, gemcitabine and pegaspargase
C0040808||regimen
C0040808||protocol treatment
C0936012||analysis
C1254351||dexamethasone, gemcitabine and pegaspargase
C3665472||chemotherapy
C1275810||complete response
C1275810||complete response
C1521726||partial response
C1521726||partial response
C1335499||progressive disease
C1335499||progressive disease
C1522577||follow-up
C0441800||Grade
C0023530||leukopenia
C0441800||grade
C0040034||thrombocytopenia
C0030605||Activated Partial Phromboplastin Ptime
C0030605||Activated Partial Phromboplastin Ptime
C0240671||elongation
C0553681||hypofibrinogenemia
C1254351||dexamethasone, gemcitabine and pegaspargase
C0040808||regimen
C0013220||tolerated
C0392788||extranodal natural killer/T-cell lymphoma, nasal type
C0008976||trial
C1514821||registered
C2349146||www.ClinicalTrials.gov